{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:46:20Z","timestamp":1792698380036,"version":"4.5.0"},"reference-count":250,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016402","name":"Mackenzie Charatible Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001530","name":"Canterbury Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002101","name":"Division of Health Sciences, University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Gliomas are a heterogeneous group of cancers that predominantly arise from glial cells in the brain, but may also arise from neural stem cells, encompassing low-grade glioma and high-grade glioblastoma. Whereas better diagnosis and new treatments have improved patient survival for many cancers, glioblastomas remain challenging with a highly unfavorable prognosis. This review discusses a super-family of enzymes, the 2-oxoglutarate dependent dioxygenase enzymes (2-OGDD) that control numerous processes including epigenetic modifications and oxygen sensing, and considers their many roles in the pathology of gliomas. We specifically describe in more detail the DNA and histone demethylases, and the hypoxia-inducible factor hydroxylases in the context of glioma, and discuss the substrate and cofactor requirements of the 2-OGDD enzymes. Better understanding of how these enzymes contribute to gliomas could lead to the development of new treatment strategies.<\/jats:p>","DOI":"10.3389\/fonc.2021.619300","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T09:17:15Z","timestamp":1616663835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response"],"prefix":"10.3389","volume":"11","author":[{"given":"Rebekah L. I.","family":"Crake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor R.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice A.","family":"Royds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet C. M.","family":"Vissers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi U.","family":"Dachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2217\/epi.13.79","article-title":"The roles of Jumonji-type oxygenases in human disease","volume":"6","author":"Johansson","year":"2014","journal-title":"Epigenomics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2010.08.006","article-title":"Structural studies on human 2-oxoglutarate dependent oxygenases","volume":"20","author":"McDonough","year":"2010","journal-title":"Curr Opin Struct Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio863","article-title":"Non-heme dioxygenases: Cellular sensors and regulators jelly rolled into one","volume":"3","author":"Ozer","year":"2007","journal-title":"Nat Chem Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.14670\/HH-29.991","article-title":"The role of TET family proteins and 5-hydroxymethylcytosine in human tumors","volume":"29","author":"Wu","year":"2014","journal-title":"Histol Histopathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-biochem-061516-044724","article-title":"2-Oxoglutarate-Dependent Oxygenases","volume":"87","author":"Islam","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"B7","first-page":"71","article-title":"Ascorbate as an Enzyme Cofactor. In: Vitamin C. CRC Press Taylor and Francis Group, Florida, USA. (2020) pp","author":"Vissers","year":"2020"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2741\/4160","article-title":"Effects of vitamin C on health: A review of evidence","volume":"18","author":"Grosso","year":"2013","journal-title":"Front Biosci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00282.x","article-title":"Vitamin C: update on physiology and pharmacology","volume":"157","author":"Mandl","year":"2009","journal-title":"Br J Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1042\/BST20140118","article-title":"Regulation of the 2-oxoglutarate-dependent dioxygenases and implications for cancer","volume":"42","author":"Vissers","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.09.010","article-title":"Ascorbate-induced generation of 5-hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate","volume":"439","author":"Dickson","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312254200","article-title":"Catalytic Properties of the Asparaginyl Hydroxylase (FIH) in the Oxygen Sensing Pathway Are Distinct from Those of Its Prolyl 4-Hydroxylases","volume":"279","author":"Koivunen","year":"2004","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2007.1683","article-title":"Regulated function of the prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins","volume":"9","author":"Nytko","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12432","article-title":"WHO 2016 Classification of gliomas","volume":"44","author":"Wesseling","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12328-8","article-title":"Primary brain tumours in adults","volume":"361","author":"Behin","year":"2003","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1996.tb00848.x","article-title":"Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas","volume":"6","author":"Watanabe","year":"1996","journal-title":"Brain Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/cancers9060057","article-title":"Chemotherapeutic drugs: DNA damage and repair in glioblastoma","volume":"9","author":"Annovazzi","year":"2017","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4952","article-title":"Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches (review)","volume":"12","author":"Huang","year":"2016","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0513-5117(09)79085-4","article-title":"IDH1 and IDH2 Mutations in Gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.031","article-title":"Recent developments in the use of chemotherapy in brain tumours","volume":"42","author":"Van Den Bent","year":"2006","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/bjc.2012.504","article-title":"Systematic review and meta-analysis of temozolomide in animal models of glioma: Was clinical efficacy predicted","volume":"108","author":"Hirst","year":"2013","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/foc.2006.20.4.2","article-title":"Recurrent glioblastoma multiforme: a review of natural history and management options","volume":"20","author":"Hou","year":"2006","journal-title":"Neurosurg Focus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1107\/S2052252514020922","article-title":"Structure and function of dioxygenases in histone demethylation and DNA\/RNA demethylation","volume":"1","author":"Dong","year":"2014","journal-title":"IUCrJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2218","article-title":"Histone lysine demethylases: Emerging roles in development, physiology and disease","volume":"8","author":"Shi","year":"2007","journal-title":"Nat Rev Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2012.10.002","article-title":"Nucleic acid modifications with epigenetic significance","volume":"16","author":"Fu","year":"2012","journal-title":"Curr Opin Chem Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.devcel.2010.10.005","article-title":"Developmental Cell Review Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry","volume":"19","author":"Berdasco","year":"2010"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.11.010","article-title":"Glioma epigenetics: From subclassification to novel treatment options","volume":"51","author":"Gusyatiner","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/neuonc\/noq110","article-title":"Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis","volume":"13","author":"Laffaire","year":"2011","journal-title":"Neuro Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/ng.3457","article-title":"Integrated genomic characterization of IDH1-mutant glioma malignant progression","volume":"48","author":"Bai","year":"2015","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.07.012","article-title":"DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors","volume":"28","author":"Mazor","year":"2015","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.107","article-title":"A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence","volume":"23","author":"de Souza","year":"2018","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-43790-7","article-title":"DNA demethylation is associated with malignant progression of lower-grade gliomas","volume":"9","author":"Nomura","year":"2019","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13148-019-0670-9","article-title":"Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas","volume":"11","author":"Yin","year":"2019","journal-title":"Clin Epigenet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2013.115","article-title":"Oxidative bisulfite sequencing of 5-methylcytosine and 5- hydroxymethylcytosine","volume":"8","author":"Booth","year":"2013","journal-title":"Nat Protoc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.02.004","article-title":"Dynamic readers for 5-(Hydroxy)methylcytosine and its oxidized derivatives","volume":"152","author":"Spruijt","year":"2013","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-10-r119","article-title":"A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation","volume":"14","author":"Iurlaro","year":"2013","journal-title":"Genome Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2023","article-title":"5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations","volume":"71","author":"Jin","year":"2011"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27429","article-title":"Low values of 5-hydroxymethylcytosine (5hmC), the \u2018sixth base,\u2019 are associated with anaplasia in human brain tumors","volume":"131","author":"Kraus","year":"2012","journal-title":"Int J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3606-9","article-title":"Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma","volume":"36","author":"Kraus","year":"2015","journal-title":"Tumor Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms13177","article-title":"5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy214","article-title":"Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma","volume":"27","author":"Fernandez","year":"2018","journal-title":"Orig Artic Hum Mol Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.04.017","article-title":"Nuclear exclusion of TET1 is associated with loss of 5- hydroxymethylcytosine in IDH1 wild-type gliomas","volume":"181","author":"Waha","year":"2012","journal-title":"Am J Pathol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e41036","DOI":"10.1371\/journal.pone.0041036","article-title":"Decreased 5-Hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma","volume":"7","author":"Orr","year":"2012","journal-title":"PloS One"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1821-3","article-title":"5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma","volume":"135","author":"Glowacka","year":"2018","journal-title":"Acta Neuropathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature12750","article-title":"TET enzymes, TDG and the dynamics of DNA demethylation","volume":"502","author":"Kohli","year":"2013","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.1169786","article-title":"Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA","volume":"333","author":"He","year":"2011","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2217\/epi.12.36","article-title":"DNA demethylation by TDG","volume":"4","author":"Dalton","year":"2012","journal-title":"Epigenomics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"82961","DOI":"10.1371\/journal.pone.0082961","article-title":"Cell Cycle-Dependent Turnover of 5-Hydroxymethyl Cytosine in Mouse Embryonic Stem Cells","volume":"8","author":"Otani","year":"2013","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.12.4.905","article-title":"Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme","volume":"12","author":"Fults","year":"1998","journal-title":"Int J Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-004-2747-2","article-title":"Molecular pathogenesis of astrocytic tumours","volume":"70","author":"Ichimura","year":"2004","journal-title":"J Neurooncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1996.tb00231.x","article-title":"Deletion Mapping of Chromosome 10 in Human Glioma","volume":"87","author":"Sonoda","year":"1996","journal-title":"Japan J Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6288","article-title":"Repression of the expression of TET2 by ZEB1 contributes to invasion and growth in glioma cells","volume":"15","author":"Chen","year":"2017","journal-title":"Mol Med Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25406","article-title":"Epigenetic dysregulation of TET2 in human glioblastoma","volume":"9","author":"Garc\u00eda","year":"2018","journal-title":"Oncotarget"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32520","article-title":"Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis","volume":"146","author":"Carella","year":"2020","journal-title":"Int J Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2011-200133","article-title":"TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1\/2 mutations","volume":"64","author":"Kim","year":"2011","journal-title":"J Clin Pathol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7150\/jca.12010","article-title":"Genetic characterization of ten-eleven-translocation methylcytosine dioxygenase alterations in human glioma","volume":"6","author":"Kraus","year":"2015","journal-title":"J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1945","article-title":"JmjC-domain-containing proteins and histone demethylation","volume":"7","author":"Klose","year":"2006","journal-title":"Nat Rev Genet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1761","article-title":"The diverse functions of histone lysine methylation","volume":"6","author":"Martin","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.78.070907.103946","article-title":"Reversal of Histone Methylation: Biochemical and Molecular Mechanisms of Histone Demethylases","volume":"79","author":"Mosammaparast","year":"2010","journal-title":"Annu Rev Biochem"},{"key":"B73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/AN20130050","article-title":"Cell-type-specific Jumonji histone demethylase gene expression in the healthy rat CNS: Detection by a novel flow cytometry method","volume":"6","author":"Smith","year":"2014","journal-title":"ASN Neuro"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2015.07.030","article-title":"Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases","volume":"1628","author":"Karuppagounder","year":"2015","journal-title":"Brain Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14348\/molcells.2014.2250","article-title":"HIF-1-dependent induction of jumonji domain-containing protein (JMJD) 3 under hypoxic conditions","volume":"37","author":"Lee","year":"2014","journal-title":"Mol Cells"},{"key":"B76","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12935-020-01177-z","article-title":"The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0454","article-title":"Global histone modification patterns as prognostic markers to classify glioma patients","volume":"19","author":"Liu","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.10.078","article-title":"Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21","volume":"454","author":"Dai","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1090063","article-title":"The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma","volume":"14","author":"Banelli","year":"2015","journal-title":"Cell Cycle"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12174","article-title":"Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B","volume":"12","author":"Staberg","year":"2018","journal-title":"Mol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nature06255","article-title":"JHDM1B\/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes","volume":"450","author":"Frescas","year":"2007","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e51407","DOI":"10.1371\/journal.pone.0051407","article-title":"Histone Demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Protein Nuclear Stabilization","volume":"7","author":"Ene","year":"2012","journal-title":"PloS One 7"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","journal-title":"Nat Genet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"Nat Publ Gr"},{"key":"B87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells6040045","article-title":"The role of hypoxia in glioblastoma invasion","volume":"6","author":"Monteiro","year":"2017","journal-title":"Cells"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4995","article-title":"Regional hypoxia in glioblastoma multiforme quantified with [ 18F] fluoromisonidazole positron emission tomography before radiotherapy: Correlation with time to progression and survival","volume":"14","author":"Spence","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2007.07.080","article-title":"Expression of hypoxia inducible factor-1\u03b1 in tumors of patients with glioblastoma multiforme and transitional meningioma","volume":"15","author":"Kaynar","year":"2008","journal-title":"J Clin Neurosci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-9827-2","article-title":"Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target","volume":"92","author":"Jensen","year":"2009","journal-title":"J Neuro-oncol Neurooncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059817","article-title":"HIF\u03b1 targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1101\/gad.924501","article-title":"FIH-1: A novel protein that interacts with HIF-1\u03b1 and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C200273200","article-title":"Hypoxia-inducible Factor (HIF) Asparagine Hydroxylase Is Identical to Factor Inhibiting HIF (FIH) and Is Related to the Cupin Structural Family*","volume":"277","author":"Hewitson","year":"2002"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059817","article-title":"Targeting of HIF-alpha to to the von Hippel\u2013Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation","volume":"292","author":"Jaakola","year":"2001","journal-title":"Science"},{"key":"B96","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314427","article-title":"High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq","volume":"117","author":"Sch\u00f6del","year":"2011","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M901790200","article-title":"Genome-wide association of hypoxia-inducible factor (HIF)-1\u03b1 and HIF-2\u03b1 DNA binding with expression profiling of hypoxia-inducible transcripts","volume":"284","author":"Mole","year":"2009","journal-title":"J Biol Chem"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1996.0311","article-title":"Assignment of the hypoxia-inducible factor 1\u03b1 gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q","volume":"34","author":"Semenza","year":"1996","journal-title":"Genomics"},{"key":"B101","unstructured":""},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.15.8104","article-title":"Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth","volume":"94","author":"Maxwell","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nm0597-515","article-title":"Targeting gene expression to hypoxic tumor cells","volume":"3","author":"Dachs","year":"1997","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-4797-6_34","article-title":"Molecular Biology of Hypoxia-Inducible Factor-1","author":"Wenger","year":"1999","journal-title":"Mol Biol Hematopoiesis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1 \u03b1 and HIF2 \u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846401","article-title":"Inherent DNA binding specificities of the HIF-1\u03b1 and HIF-2\u03b1 transcription factors in chromatin","volume":"20","author":"Smythies","year":"2019","journal-title":"EMBO Rep"},{"key":"B107","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"2","author":"Majmundar","year":"2010","journal-title":"Mol Cell"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1039\/b701676j","article-title":"The human oxygen sensing machinery and its manipulation","volume":"37","author":"Chowdhury","year":"2008","journal-title":"Chem Soc Rev"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.10.005","article-title":"Advances in Hypoxia-Inducible Factor Biology","volume":"27","author":"Choudhry","year":"2018","journal-title":"Cell Metab"},{"key":"B110","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.3171\/foc.2006.20.4.16","article-title":"Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures","volume":"20","author":"Jensen","year":"2006","journal-title":"Neurosurg Focus"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2003.00535.x","article-title":"Hypoxia-inducible factor 1a\/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis","volume":"30","author":"Korkolopoulou","year":"2004","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.9929","article-title":"Clinical implications of hypoxia-inducible factor-1alpha and caveolin-1 overexpression in isocitrate dehydrogenase-wild type glioblastoma multiforme","volume":"17","author":"Chen","year":"2019","journal-title":"Oncol Lett"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W","article-title":"Expression of hypoxia-inducible factor 1\u03b1 in brain tumors: Association with angiogenesis, invasion, and progression","volume":"88","author":"Zagzag","year":"2000","journal-title":"Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00249","article-title":"Hypoxia-Inducible Factor-1alpha Activity as a Switch for Glioblastoma Responsiveness to Temozolomide","volume":"8","author":"Lo Dico","year":"2018","journal-title":"Front Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-005-9103-z","article-title":"Inhibition of hypoxia inducible factor-1a (HIF-1a) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas","volume":"78","author":"Jensen","year":"2006","journal-title":"J Neurooncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2073","article-title":"Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population","volume":"64","author":"Brat","year":"2004","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2018-0163","article-title":"Hypoxia-inducible factor 2\u03b1: A novel target in gliomas","volume":"10","author":"Renfrow","year":"2018","journal-title":"Future Med Chem"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.181341498","article-title":"HIF-1\u03b1 binding to VHL is regulated by stimulus-sensitive proline hydroxylation","volume":"98","author":"Yu","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1101\/gad.991402","article-title":"FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor","volume":"16","author":"Lando","year":"2002","journal-title":"Genes Dev"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.002436","article-title":"Asparagine hydroxylation is a reversible post-translational modification","volume":"13","author":"Rodriguez","year":"2020","journal-title":"Mol Cell Proteomics"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1039\/b511249b","article-title":"Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate","volume":"1","author":"McNeill","year":"2005","journal-title":"Mol Biosyst"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601283103","article-title":"Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)","volume":"103","author":"McDonough","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg392","article-title":"HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1\u03b1 in normoxia","volume":"22","author":"Berra","year":"2003","journal-title":"EMBO J"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00318","article-title":"Intracellular localisation of human HIF-1\u03b1 hydroxylases: Implications for oxygen sensing","volume":"116","author":"Metzen","year":"2003","journal-title":"J Cell Sci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2019.7902","article-title":"2-hydroxyglutarate in cancer cells","volume":"33","author":"Je\u017eek","year":"2020","journal-title":"Antioxid Redox Signaling"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00303-3","article-title":"2-Oxoglutarate-dependent dioxygenases in cancer","volume":"20","author":"Losman","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nature10898","article-title":"Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation","volume":"483","author":"Koivunen","year":"2012","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-010-0790-y","article-title":"R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1\u03b1 upregulation in adult glioma","author":"Williams","year":"2011","journal-title":"Acta Neuropathol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2014.9.FOCUS14496","article-title":"Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma","volume":"37","author":"Womeldorff","year":"2014","journal-title":"Neurosurg Focus"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","article-title":"ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform","volume":"6","author":"Rhodes","year":"2004","journal-title":"Neoplasia"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e86102","DOI":"10.1371\/journal.pone.0086102","article-title":"The Role of Factor Inhibiting HIF (FIH-1) in Inhibiting HIF-1 Transcriptional Activity in Glioblastoma Multiforme","volume":"9","author":"Wang","year":"2014","journal-title":"PloS One"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0423-9","article-title":"Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1\u03b1 stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment","volume":"38","author":"Feng","year":"2019","journal-title":"Oncogene"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00359","article-title":"Ascorbate as a cofactor for Fe-and 2-oxoglutarate dependent dioxygenases: Physiological activity in tumour growth and progression","volume":"4","author":"Kuiper","year":"2014","journal-title":"Front Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/54.6.1147s","article-title":"Ascorbic acid and carnitine biosynthesis","volume":"54","author":"Rebouche","year":"1991","journal-title":"Am J Clin Nutr"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304982200","article-title":"Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor","volume":"278","author":"Hirsil\u00e4","year":"2003","journal-title":"J Biol Chem"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.6.1173","article-title":"Characterization of the iron- and 2-oxoglutavate binding sites of human prolyl 4-hydroxylase","volume":"16","author":"Myllyharju","year":"1997","journal-title":"EMBO J"},{"key":"B137","first-page":"1","article-title":"Partial pressure of oxygen in the human body: a general review","volume":"9","author":"Ortiz-Prado","year":"2019","journal-title":"Am J Blood Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-3019(96)00473-9","article-title":"Cerebral interstitial tissue oxygen tension, pH, HCO3, CO2","volume":"48","author":"Charbel","year":"1997","journal-title":"Surg Neurol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/BF02477117","article-title":"A galvanic cell suitable for monitoring cortical oxygen in man","volume":"13","author":"Baker","year":"1975","journal-title":"Med Biol Eng"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199603000-00027","article-title":"Brain tissue oxygen, carbon dioxide, and pH in neurosurgical patients at risk for ischemia","volume":"82","author":"Hoffman","year":"1996","journal-title":"Anesth Analg"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-69360-1_45","article-title":"Measurement of Local Oxygen Partial Pressure (PO2) of the Brain Cortex in Cases of Brain Tumors","author":"Assad","year":"1984"},{"key":"B142","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/978-3-7091-9302-0_10","article-title":"Studies of tissue PO2 in normal and pathological human brain cortex","volume":"59","author":"Meixensberger","year":"1993","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199811000-00045","article-title":"Clinical Experience with 118 Brain Tissue Oxygen Partial Pressure Catheter Probes","volume":"43","author":"Dings","year":"1998","journal-title":"Neurosurgery"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2007.1628","article-title":"Detection and characterization of tumor hypoxia using pO2 histography","volume":"9","author":"Vaupel","year":"2007","journal-title":"Antioxid Redox Signaling"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90432-4","article-title":"Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors","volume":"29","author":"Rampling","year":"1994","journal-title":"Radiat Oncol Biol Phys"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.06.287","article-title":"18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy","volume":"102","author":"Qian","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B147","article-title":"Hypoxia in human gliomas: Demonstration by PET with fluorine-18-fluoromisonidazole","volume":"33","author":"Valk","year":"1993","journal-title":"Artic J Nucl Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.09265","article-title":"The relationship among hypoxia, proliferation, and outcome in patients with de nouo glioblastoma: A pilot study","volume":"3","author":"Evans","year":"2010","journal-title":"Transl Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0076-6879(02)52003-6","article-title":"Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5","volume":"352","author":"Koch","year":"2002","journal-title":"Methods Enzymol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(99)00121-8","article-title":"Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue","volume":"53","author":"Collingridge","year":"1999","journal-title":"Radiother Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-9334-1_101","article-title":"Peri-tumoural hypoxia in human brain: peroperative measurement of the tissue oxygen tension around malignant brain tumours","volume":"60","author":"Cruickshank","year":"1994","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-016-0814-0","article-title":"Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours","volume":"33","author":"St\u0119pie\u0144","year":"2016","journal-title":"Med Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3143","article-title":"Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer Trial 22933","volume":"17","author":"Miralbell","year":"1999","journal-title":"J Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3171\/2016.3.JNS152693","article-title":"Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme","volume":"126","author":"Gainer","year":"2017","journal-title":"J Neurosurg"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2427-7","article-title":"GBM radiosensitizers: dead in the water\u2026or just the beginning","volume":"134","author":"Bindra","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01724-6","article-title":"Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas","volume":"39","author":"Mudassar","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B158","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-008-0455-2","article-title":"Analysis of the IDH1 codon 132 mutation in brain tumors","volume":"116","author":"Balss","year":"2008","journal-title":"Acta Neuropathol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/humu.20937","article-title":"IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors","volume":"30","author":"Bleeker","year":"2009","journal-title":"Hum Mutat"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1021\/cb500683c","article-title":"Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate","volume":"10","author":"Fan","year":"2015","journal-title":"ACS Chem Biol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1172\/JCI71180","article-title":"MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis","volume":"124","author":"Terunuma","year":"2014","journal-title":"J Clin Invest"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy148.973","article-title":"A phase 1, multicenter, randomized, openlabel, perioperative study of ag-120 (ivosidenib) and AG-881 in patients with recurrent, nonenhancing, IDH1-mutant, low-grade glioma","author":"Mellinghoff","year":"2018","journal-title":"Neuro Oncol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00771-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors","volume":"38","author":"Fan","year":"2020","journal-title":"Invest New Drugs"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.2004","article-title":"Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas","volume":"15","author":"Natsume","year":"2019","journal-title":"J Clin Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00684-6","article-title":"Novel IDH1-Targeted Glioma Therapies","volume":"33","author":"Karpel-Massler","year":"2019","journal-title":"CNS Drugs"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br J Cancer"},{"key":"B167","doi-asserted-by":"publisher","first-page":"12758","DOI":"10.1038\/s41598-017-12630-x","article-title":"Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays","volume":"7","author":"Urban","year":"2017","journal-title":"Sci Rep"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0929-9","article-title":"Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma","volume":"38","author":"Nakagawa","year":"2019","journal-title":"Oncogene"},{"key":"B169","doi-asserted-by":"publisher","first-page":"vi79","DOI":"10.1093\/neuonc\/nox168.326","article-title":"EXTH-34. Combined use of the pan IDH mutant inhibitor AG-881 with radiation therapy shoes added benefit in an orthotopic IDH1 mutant glioma model in vivo","volume":"19","author":"Nicolay","year":"2017","journal-title":"Neuro Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1677-y","article-title":"Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo","volume":"133","author":"Pusch","year":"2017","journal-title":"Acta Neuropathol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher","year":"2014","journal-title":"Nature"},{"key":"B172","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40478-014-0180-0","article-title":"Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma","volume":"3","author":"Pellegatta","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.69020443.x","article-title":"Transport of iron in the blood-brain-cerebrospinal fluid system","volume":"69","author":"Bradbury","year":"1997","journal-title":"J Neurochem"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21020","article-title":"Iron metabolism in parkinsonian syndromes","volume":"21","author":"Berg","year":"2006","journal-title":"Mov Disord"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.769240","article-title":"Na+\/H+ Exchanger 9 Regulates Iron Mobilization at the Blood-Brain Barrier in Response to Iron Starvation *","volume":"292","author":"Beydoun","year":"2017"},{"key":"B177","doi-asserted-by":"publisher","first-page":"89003","DOI":"10.1371\/journal.pone.0089003","article-title":"Glial Cell Ceruloplasmin and Hepcidin Differentially Regulate Iron Efflux from Brain Microvascular Endothelial Cells","volume":"9","author":"McCarthy","year":"2014","journal-title":"PloS One"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1002\/glia.21166","article-title":"Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase a pathway","volume":"59","author":"Du","year":"2011","journal-title":"Glia"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.10.083","article-title":"Regulatory mechanisms for iron transport across the blood-brain barrier","volume":"494","author":"Duck","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.2013007784","article-title":"Cellular iron metabolism in prognosis and therapy of breast cancer","volume":"18","author":"Torti","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2018.02.010","article-title":"Iron transport kinetics through blood-brain barrier endothelial cells","volume":"1862","author":"Khan","year":"2018","journal-title":"Biochim Biophys Acta  Gen Subj"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19990415)56:2<113::AID-JNR1>3.0.CO;2-K","article-title":"Existing and emerging mechanisms for transport of iron and manganese to the brain","volume":"56","author":"Malecki","year":"1999","journal-title":"J Neurosci Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1111\/brv.12521","article-title":"Brain iron transport","volume":"94","author":"Qian","year":"2019","journal-title":"Biol Rev"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00045","article-title":"Labile iron in cells and body fluids: physiology, pathology, and pharmacology","volume":"5","author":"Cabantchik","year":"2014","journal-title":"Front Pharmacol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1771-4","article-title":"Iron transport across the blood-brain barrier: Development, neurovascular regulation and cerebral amyloid angiopathy","volume":"72","author":"McCarthy","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.455428","article-title":"Ferroportin and exocytoplasmic ferroxidase activity are required for brain microvascular endothelial cell iron efflux","volume":"288","author":"McCarthy","year":"2013","journal-title":"J Biol Chem"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.10.066","article-title":"Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier","volume":"1001","author":"Wu","year":"2004","journal-title":"Brain Res"},{"key":"B188","doi-asserted-by":"publisher","first-page":"e0166593","DOI":"10.1371\/journal.pone.0166593","article-title":"Aberrations in the Iron Regulatory Gene Signature Are Associated with Decreased Survival in Diffuse Infiltrating Gliomas","volume":"11","author":"Weston","year":"2016","journal-title":"PloS One"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.03.008","article-title":"Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies","volume":"26","author":"Legendre","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"B190","doi-asserted-by":"publisher","first-page":"xi56","DOI":"10.1093\/annonc\/mdz452.029","article-title":"Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients","volume":"30","author":"Magri","year":"2019","journal-title":"Ann Oncol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12967-018-1399-5","article-title":"Hepcidin, an emerging and important player in brain iron homeostasis","volume":"16","author":"Vela","year":"2018","journal-title":"J Trans Med"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.002","article-title":"Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells","volume":"28","author":"Schonberg","year":"2015","journal-title":"Cancer Cell"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20091609","article-title":"Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents","volume":"427","author":"Flashman","year":"2010","journal-title":"Biochem J"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C113.464800","article-title":"Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine","volume":"288","author":"Minor","year":"2013","journal-title":"J Biol Chem"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2008.12.018","article-title":"Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2","volume":"46","author":"Harrison","year":"2009","journal-title":"Free Radic Biol Med"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2015.00397","article-title":"Vitamin C in health and disease: Its role in the metabolism of cells and redox state in the brain","volume":"6","author":"Figueroa-M\u00e9ndez","year":"2015","journal-title":"Front Physiol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1975.tb29271.x","article-title":"Distribution of ascorbic acid, metabolites and analogues in man and animals","volume":"258","author":"Hornig","year":"1975"},{"key":"B198","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4172\/2157-7633.1000209","article-title":"Vitamin C Transporters, Recycling and the Bystander Effect in the Nervous System: SVCT2 versus Gluts","volume":"4","author":"Nualart","year":"2014","journal-title":"J Stem Cell Res Ther"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1007\/BF01052896","article-title":"Levels of water-soluble antioxidants in astrocytoma and in adjacent tumor-free tissue","volume":"21","author":"Landolt","year":"1994","journal-title":"J Neurooncol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/nature12362","article-title":"Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells","volume":"500","author":"Blaschke","year":"2013","journal-title":"Nature"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608679113","article-title":"Retinol and ascorbate drive erasure of Epigenetic memory and enhance reprogramming to na\u00efve pluripotency by complementary mechanisms","volume":"113","author":"Hore","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B202","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13148-019-0739-5","article-title":"Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes","volume":"11","author":"Gillberg","year":"2019","journal-title":"Clin Epigenet"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0527-7","article-title":"Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer","volume":"10","author":"Peng","year":"2018","journal-title":"Clin Epigenet"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"B205","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-019-0242-4","article-title":"Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1","volume":"9","author":"Das","year":"2019","journal-title":"Blood Cancer J"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2019.1666652","article-title":"Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells","volume":"15","author":"Gerecke","year":"2020","journal-title":"Epigenetics"},{"key":"B207","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/leu.2017.171","article-title":"Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia","volume":"32","author":"Mingay","year":"2018","journal-title":"Leukemia"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.10.005","article-title":"The histone demethylases Jhdm1a\/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner","volume":"9","author":"Wang","year":"2011","journal-title":"Cell Stem Cell"},{"key":"B209","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13072-017-0143-3","article-title":"Vitamin C induces specific demethylation of H3K9me2 in mouse embryonic stem cells via Kdm3a\/b","volume":"10","author":"Ebata","year":"2017","journal-title":"Epigenet Chromatin"},{"key":"B210","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5483\/BMBRep.2017.50.1.193","article-title":"Vitamin C enhances the expression of IL17 in a Jmjd2-dependent manner","volume":"50","author":"Song","year":"2017","journal-title":"BMB Rep"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1002\/stem.493","article-title":"Vitamin C promotes widespread yet specific DNA demethylation of the epigenome in human embryonic stem cells","volume":"28","author":"Chung","year":"2010","journal-title":"Stem Cells"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2014.01.033","article-title":"Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response","volume":"69","author":"Kuiper","year":"2014","journal-title":"Free Radic Biol Med"},{"key":"B213","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/HP.S103088","article-title":"Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in gulo-\/- mice","volume":"4","author":"Dachs","year":"2016","journal-title":"Hypoxia"},{"key":"B214","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-017-0388-y","article-title":"Expression of hypoxia inducible factor 1\u03b1 and 2\u03b1 and its association with Vitamin C level in thyroid lesions","volume":"24","author":"J\u00f3\u017awiak","year":"2017","journal-title":"J Biomed Sci"},{"key":"B215","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/HP.S201643","article-title":"Ascorbate modulates the hypoxic pathway by increasing intracellular activity of the HIF hydroxylases in renal cell carcinoma cells","volume":"7","author":"Wohlrab","year":"2019","journal-title":"Hypoxia"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.349","article-title":"Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo \u2013\/\u2013 mice","volume":"4","author":"Campbell","year":"2015","journal-title":"Cancer Med"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0263","article-title":"Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer","volume":"70","author":"Kuiper","year":"2010","journal-title":"Cancer Res"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00010","article-title":"Increased tumor ascorbate is associated with extended disease-free survival and decreased hypoxia-inducible factor-1 activation in human colorectal cancer","volume":"4","author":"Kuiper","year":"2014","journal-title":"Front Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00574","article-title":"The Association Between Ascorbate and the Hypoxia-Inducible Factors in Human Renal Cell Carcinoma Requires a Functional Von Hippel-Lindau Protein","volume":"8","author":"Wohlrab","year":"2018","journal-title":"Front Oncol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12885-019-5503-x","article-title":"Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels","volume":"19","author":"Campbell","year":"2019","journal-title":"BMC Cancer"},{"key":"B221","doi-asserted-by":"publisher","first-page":"e11414","DOI":"10.1371\/journal.pone.0011414","article-title":"Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects","volume":"5","author":"Padayatty","year":"2010","journal-title":"PloS One"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197909273011303","article-title":"Failure of high-dose vitamin C therapy to benefit patients with advanced cancer","volume":"301","author":"Creagan","year":"1979","journal-title":"N Engl J Med"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198501173120301","article-title":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy","volume":"312","author":"Moertel","year":"1985","journal-title":"N Engl J Med"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.9.4538","article-title":"Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer","volume":"75","author":"Cameron","year":"1978","journal-title":"Proc Natl Acad Sci"},{"key":"B225","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0009-2797(74)90019-2","article-title":"The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer","volume":"9","author":"Cameron","year":"1974","journal-title":"Chem Interact"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C Pharmacokinetics\u202f: Implications for Oral and IV use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann Intern Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2179-9","article-title":"Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer","volume":"72","author":"Stephenson","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B228","doi-asserted-by":"publisher","first-page":"(15AD)","DOI":"10.1111\/bcpt.12323","article-title":"Elimination of Ascorbic Acid following High-Dose Infusion in Prostate Cancer Patients: A Pharmacokinetic Evaluation","volume":"116","author":"Nielsen","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn377","article-title":"Phase I clinical trial of i.v. ascorbic acid in advanced malignancy","volume":"19","author":"Hoffer","year":"1969","journal-title":"Ann Oncol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2003.10719284","article-title":"The Use of Antioxidants with First-Line Chemotherapy in Two Cases of Ovarian Cancer","volume":"22","author":"Drisko","year":"2003","journal-title":"J Am Coll Nutr"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050346","article-title":"Intravenously administered vitamin C as cancer therapy: Three cases","volume":"174","author":"Padayatty","year":"2006","journal-title":"CMAJ"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-189","article-title":"Effect of high-dose intravenous vitamin C on inflammation in cancer patients","volume":"10","author":"Mikirova","year":"2012","journal-title":"J Transl Med"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2070-8","article-title":"Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial","volume":"71","author":"Welsh","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"222ra18","DOI":"10.1126\/scitranslmed.3007154","article-title":"High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy","volume":"6","author":"Ma","year":"2014","journal-title":"Sci Transl Med"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2015.56.5.1449","article-title":"High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma","volume":"56","author":"Seo","year":"2015","journal-title":"Yonsei Med J"},{"key":"B236","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1534735415622010","article-title":"Effects of High Doses of Vitamin C on Cancer Patients in Singapore: Nine Cases","volume":"15","author":"Raymond","year":"2016","journal-title":"Integr Cancer Ther"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.899754","article-title":"High-dose intravenous vitamin C treatment of a child with neurofibromatosis type 1 and optic pathway glioma: A case report","volume":"17","author":"Mikirova","year":"2016","journal-title":"Am J Case Rep"},{"key":"B238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17568-8","article-title":"High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: Mechanisms and a phase I\/IIa study","volume":"7","author":"Polireddy","year":"2017","journal-title":"Sci Rep"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5696-z","article-title":"Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"key":"B240","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccell.2017.02.018","article-title":"O 2 \u00b7\u2013 and H 2 O 2 -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate","volume":"31","author":"Schoenfeld","year":"2017","journal-title":"Cancer Cell"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00356","article-title":"Pharmacological doses of daily ascorbate protect tumors from radiation damage after a single dose of radiation in an intracranial mouse glioma model","volume":"4","author":"Grasso","year":"2014","journal-title":"Front Oncol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.01.021","article-title":"Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2\/M arrest","volume":"52","author":"Herst","year":"2012","journal-title":"Free Radic Biol Med Biol Med"},{"key":"B243","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.freeradbiomed.2017.09.008","article-title":"Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis","volume":"113","author":"Ma","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2014.06.022","article-title":"Radiosensitisation by pharmacological ascorbate in glioblastoma multiforme cells, human glial cells, and HUVECs depends on their antioxidant and DNA repair capabilities and is not cancer specific","volume":"74","author":"Castro","year":"2014","journal-title":"Free Radic Biol Med"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0594","article-title":"First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma","volume":"25","author":"Bodeker","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.3390\/antiox7090115","article-title":"The use of intravenous vitamin C as a supportive therapy for a patient with glioblastoma multiforme","volume":"7","author":"Baillie","year":"2018","journal-title":"Antioxidants"},{"key":"B247","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"B248","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0079-6603(08)60879-X","article-title":"Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase","volume":"51","author":"Pegg","year":"1995","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.4103\/2045-9912.229600","article-title":"Hyperbaric oxygen therapy as adjunctive strategy in treatment of glioblastoma multiforme","volume":"8","author":"Huang","year":"2018","journal-title":"Med Gas Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.619300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T09:17:24Z","timestamp":1616663844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.619300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":250,"alternative-id":["10.3389\/fonc.2021.619300"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.619300","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"article-number":"619300"}}